96 results about "Blood substitute" patented technology

An apparatus and method are described for quickly inducing therapeutic hypothermia of the heart by perfusing the myocardium with hypothermic fluid in alternatingly antegrade and retrograde directions. The apparatus and method provide rapid cooling of the affected myocardium to achieve optimal myocardial salvage in a patient experiencing acute myocardial infarction. The therapeutic hypothermia system includes one or more coronary artery perfusion catheters, a coronary sinus perfusion catheter and a fluid source for delivering a hypothermically-cooled physiologically-acceptable fluid, such as saline solution, oxygenated venous blood, autologously-oxygenated arterial blood and/or an oxygenated blood substitute. The system may also include one or more guidewires, subselective catheters and/or interventional catheters introduced through a lumen in one or more of the perfusion catheters.

Artificial plasma-like solutions and methods for their use are provided. The subject solutions include: electrolytes and an oncotic agent. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.

The present invention describes, inter alia, oxygen delivery agents or blood substitutes comprising a fluorinated gas and a stabilizing material, uses for the oxygen delivery agents or blood substitutes, and apparatus for making and delivering the oxygen delivery agents or blood substitutes.

A liquid plasma expander or resuscitation fluid composition for use in a subject in need thereof, comprising, consisting of, or consisting essentially of: (a) a keratin derivative (preferably alpha keratose, gamma keratose, or combinations thereof, and with basic alpha keratose preferred over acidic alpha keratose); and (b) an electrolyte solution, with the keratin derivative solubilized in the electrolyte solution to form a homogeneous liquid composition. Blood substitutes formed therefrom and methods of making and using the same are also described.

A non-pyrogenic, endotoxin-free, stroma-free, blood substitute capable of being used in humans or other mammals to provide oxygen to tissue and to deliver carbon dioxide to the lung and a process for its preparation are described.

The invention relates to a method for extracting high-purity hemoglobin from pig blood, and on the condition of 2 to 6 DEG C, the following operations are carried out sequentially: first, anticoagulant pig blood is used for preparing packed red blood cells; hypotonic solution is used for dissolving packed red blood cells, in which inert gas is pumped, antioxidant is added, the pH value of the solution is adjusted and protective agent and antibacterial drugs are added, and after high-speed centrifugation, crude hemoglobin solution is obtained; toluene is added into the crude hemoglobin solution which is extracted in low temperature and the hemoglobin solution in the lower layer is extracted for dialysis; after being frozen and dried the hemoglobin solution after dialysis is then dissolved into high-concentration and small-volume liquid which is then purified by a sephadex chromatography column as a sample and high-concentration hemoglobin with even molecular weight is obtained to be frozen and dried in vacuum after being filtered for removing pyrogen so as to prepare high-concentration hemoglobin dry powder with no matrix or pyrogen. The hemoglobin obtained through the method of the invention has no matrix or pyrogen, which can be further modified to produce blood substitute safely and effectively and the operation is simple; the cost is low.

Disclosed are improved methods and compositions for use in light-based in vivo imaging and treatment. The techniques described involve the use of low-scattering, oxygen-carrying blood substitutes in imaging and treatment methods, including OCT imaging. The invention has particular advantages in imaging within the cardiovascular system and highly vascularized or oxygen-dependent tissues.

An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or an exocapsid form when fused at the N terminus. These fusion proteins may self-assemble into a variety of useful higher polymeric forms, e.g., capsid or other polymeric aggregate, and they are advantageous in that they are useful in a variety of applications, including human and veterinary vaccines and therapeutics, blood substitutes, image contrast agents, metal chelating agents, gelling agents, protein purification platforms, and therapeutic receptor-binding proteins.

The invention relates to a water-soluble perfluorooctyl bromide-liposome nanosphere with a mean grain size of 30-800nm, the water-soluble perfluorooctyl bromide-liposome nanosphere structure is formed as follows: inner layer perfluorooctyl bromide (PFOB) is coated with outer layer lecithin bilayer to form a liposome nanosphere, the perfluorooctyl bromide-liposome nanosphere is negative in surface charge and is good in water-soluble property, an outer coating layer of the water-soluble perfluorooctyl bromide-liposome nanosphere is the well-biocompatible lecithin bilayer which can degrade in vivo, may not produce toxic and side effects on human body, the perfluorooctyl bromide-liposome nanosphere can be used as ultrasound diagnostic reagents and blood substitutes, and the particle size is easy to control and regulate, so that the application field is expanded. The preparation process of the perfluorooctyl bromide-liposome nanosphere is very simple in operation and low in requirement on equipment, and can be used for continuous production.

The functional characteristics of heme proteins can be modified to produce hemoglobins that can be used as blood substitutes in different therapeutic applications. Stable polymers of tetrameric hemoglobin, and of myoglobin molecules, are provided for use in the blood substitutes.

An oxygen delivery system is disclosed. The basis of the oxygen deliver system is a carbide-derived carbon (CDC). The CDC can be tuned to carry O₂ directly (CDC OC), or hemoglobin can be adsorbed to provide a hemoglobin-based oxygen carrier (CDC HBOC). The delivery system allows the use of a variety of hemoglobins which differ in their oxygen dissociation profiles, including variant and mutant hemoglobins from other species. The delivery system is biocompatible and stable, and is able to irreversibly bind and hold large amounts of functional hemoglobin variants. The CDC HBOC and CDC OC provide a safe and effective blood substitute for combat casualty care, as well as being useful for oxygen delivery in other contexts.

The present invention provides a method for monitoring degradation of Hb-based blood substitutes, in a sample. This method comprises determining a concentration of met-Hb within the sample, by applying a calibration algorithm for met-Hb to an absorbance obtained from the sample at one or more than one wavelengths, and using the concentration of met-Hb, as a measurement of degradation of the Hb-based blood substitutes. Using this assay, a concentration of met-Hb that is equal to or greater than 3% may be used as an indicator of degradation of Hb. Alternatively, by obtaining samples over a period of time, the concentration of met-Hb and the concentration of Hb-based blood substitute may be determined in each of these samples, and an increase in the concentration of met-Hb over the period of time is an indicator of degradation of Hb. The sample may be a whole blood sample, a serum sample, or a plasma sample obtained from a patient transfused with one or more than one Hb-based blood substitutes, a stock Hb-based blood substitute sample, or a body part of a patient.

Described herein is the use of elastin-like polypeptides to generate hemoglobin-based oxygen carriers as a means of preventing and treating conditions caused by blood loss or anemia, for example, hemorrhagic shock. Elastin-like polypeptides are capable of creating therapeutically functional fusion proteins through genetic engineering with a therapeutic agent, for example, hemoglobin and biologic equivalent thereof. Specific forms of these fusion proteins have the ability to form into spherical nanoparticles possessing a therapeutically agent at their core. This provides a unique basis for employing elastin-like polypeptides as hemoglobin carriers in the manufacture of blood substitutes.

The invention provides a hemoglobin-human serum albumin conjugate and a preparation method thereof. By preparing stroma-free hemoglobin, then coupling hemoglobin with human serum albumin, and the coupling product is purified by ion exchange chromatography, ultrafiltration or gel filtration chromatography, and the molecular weight distribution of the coupling product is between 100KD and 300KD Among them, there are 1 to 3 hemoglobin molecules that have been intramolecularly cross-linked or not intramolecularly cross-linked and 1 to 3 human serum albumin molecules. The prepared protein conjugates have good properties of blood substitutes.